Linked Data API

Show Search Form

Search Results

1302427
star this property registered interest false more like this
star this property date less than 2021-03-15more like thismore than 2021-03-15
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that Sapropterin (Kuvan) may be prescribed in doses greater than 10mg in the event that there is an identified clinical need. more like this
star this property tabling member constituency St Albans more like this
star this property tabling member printed
Daisy Cooper more like this
star this property uin 169048 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2021-03-23more like thismore than 2021-03-23
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing evidence-based guidance for the National Health Service on whether medicines represent a clinical and cost-effective use of resources. NICE is currently developing recommendations for the NHS on the use of sapropterin for the treatment of phenylketonuria and it would not be appropriate for Ministers to intervene in the development of its guidance.</p><p>NICE published draft guidance on the use of sapropterin for consultation on 25 February 2021 which recommends its use for children under 18 up to a dose of 10mg/kg. NICE will carefully consider the comments received in developing its final recommendations. NICE expects to publish its final guidance on sapropterin in June 2021.</p> more like this
star this property answering member constituency Bury St Edmunds more like this
star this property answering member printed Jo Churchill more like this
star this property grouped question UIN 169047 more like this
star this property question first answered
less than 2021-03-23T12:44:40.907Zmore like thismore than 2021-03-23T12:44:40.907Z
star this property answering member
4380
star this property label Biography information for Jo Churchill more like this
star this property tabling member
4769
star this property label Biography information for Daisy Cooper more like this
1172561
star this property registered interest false more like this
star this property date less than 2020-01-22more like thismore than 2020-01-22
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, whether his Department has met BioMarin to discuss securing NHS access to Kuvan for people with PKU; and if he will make a statement. more like this
star this property tabling member constituency Hornsey and Wood Green more like this
star this property tabling member printed
Catherine West more like this
star this property uin 6734 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2020-01-30more like thismore than 2020-01-30
star this property answer text <p>There have been no meetings between BioMarin with Ministers and officials at the Department on this matter.</p> more like this
star this property answering member constituency Bury St Edmunds more like this
star this property answering member printed Jo Churchill more like this
star this property question first answered
less than 2020-01-30T15:39:57.247Zmore like thismore than 2020-01-30T15:39:57.247Z
star this property answering member
4380
star this property label Biography information for Jo Churchill more like this
star this property tabling member
4523
star this property label Biography information for Catherine West more like this
1141356
star this property registered interest false more like this
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of whether Kuvan should be assessed through NICE's highly-specialised technology appraisal. more like this
star this property tabling member constituency North Durham more like this
star this property tabling member printed
Mr Kevan Jones more like this
star this property uin 280943 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-08-06more like thismore than 2019-08-06
star this property answer text <p>Decisions on whether individual medicines are suitable for assessment by the National Institute for Health and Care Excellence (NICE), and whether they meet the criteria for the highly specialised technologies programme, are taken through an established topic selection process.</p><p>The process is overseen by NICE and includes consideration against published criteria by a topic selection panel and engagement with stakeholders. Although NHS England, NHS Improvement and the Department provide input and are part of this panel, the decision-making process is led by NICE. Kuvan for the treatment of phenylketonuria was last considered by the topic selection panel on 15 February 2019.</p><p>In the absence of guidance from NICE, it is for National Health Service organisations and healthcare professionals to make decisions on whether to fund Kuvan on the basis of an assessment of the available evidence. Treatment for patients with phenylketonuria who are not receiving Kuvan or for who Kuvan is not effective includes dietary protein restriction combined with dietary supplements.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency Bury St Edmunds more like this
star this property answering member printed Jo Churchill more like this
star this property question first answered
less than 2019-08-06T14:36:02.507Zmore like thismore than 2019-08-06T14:36:02.507Z
star this property answering member
4380
star this property label Biography information for Jo Churchill more like this
star this property tabling member
1438
star this property label Biography information for Mr Kevan Jones more like this
1124975
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 November 2018 to Question 190518 on Sapropterin, whether the NICE appraisal of Kuvan will take into account the costs from NHS funded treatments that can be avoided such as food supplements. more like this
star this property tabling member constituency Birmingham, Edgbaston more like this
star this property tabling member printed
Preet Kaur Gill more like this
star this property uin 251358 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>In developing its recommendations on Kuvan, the National Institute for Health and Care Excellence (NICE) will consider all the health-related costs and benefits associated with the treatment in accordance with its published methods and processes and the scope for the appraisal that has been developed in consultation with stakeholders; potentially including any costs from National Health Service funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 251357 more like this
star this property question first answered
less than 2019-05-15T16:31:51.28Zmore like thismore than 2019-05-15T16:31:51.28Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4603
star this property label Biography information for Preet Kaur Gill more like this
1122710
star this property registered interest false more like this
star this property date less than 2019-04-24more like thismore than 2019-04-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, when the National Institute for Health and Care Excellence (NICE) plans to conclude its technology appraisal for the National Health Service on the use of Kuvan for the treatment of phenylketonuria. more like this
star this property tabling member constituency North Durham more like this
star this property tabling member printed
Mr Kevan Jones more like this
star this property uin 246962 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-05-03more like thismore than 2019-05-03
star this property answer text <p>The appropriate assessment route for Kuvan (sapropterin) for the treatment of phenylketonuria has recently been reconsidered through the National Institute for Health and Care Excellence (NICE) topic selection process to take into account additional evidence presented by the company and other stakeholders, during which time NICE’s appraisal of Kuvan was paused. That process has now concluded and the topic selection decision making group has determined that Kuvan should continue to be assessed through the technology appraisal process. NICE will now schedule the topic back into the work programme as quickly as possible to allow for development of guidance without additional undue delay.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-03T13:14:03.54Zmore like thismore than 2019-05-03T13:14:03.54Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1438
star this property label Biography information for Mr Kevan Jones more like this
1005714
star this property registered interest false more like this
star this property date less than 2018-11-12more like thismore than 2018-11-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, with reference to NHS England’s appraisal of Kuvan, what steps his Department is taking to ensure that the cost offset of dietary treatments is considered in its economic assessment of the cost of commissioning new medicines. more like this
star this property tabling member constituency Hornsey and Wood Green more like this
star this property tabling member printed
Catherine West more like this
star this property uin 190518 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2018-11-20more like thismore than 2018-11-20
star this property answer text <p>NHS England has considered a policy for Kuvan (sapropterin) at the Clinical Priorities Advisory Group (CPAG) meeting on 6/7 November. Whilst NHS England did make an estimate of the current cost of protein supplements and a potential reduction in their use if Kuvan were prescribed, this cost was not included in the analysis because commissioning responsibility for supplements rests with clinical commissioning groups and it would be unlikely that NHS England would be able to realise these savings. The cost of the potential reduction in protein supplements is also relatively modest compared to the cost of Kuvan.</p><p> </p><p>In line with its published process, the recommendations from CPAG will be considered by the Specialised Commissioning Oversight Group and the Specialised Services Commissioning Committee. A decision about whether or not Kuvan has been prioritised for funding will be published in due course.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Kuvan for the treatment of phenylketonuria. In developing technology appraisal guidance, NICE takes into account all the health and publicly funded social care related costs and benefits associated with the treatment, potentially including any costs from NHS funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property grouped question UIN 190519 more like this
star this property question first answered
less than 2018-11-20T15:25:36.617Zmore like thismore than 2018-11-20T15:25:36.617Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4523
star this property label Biography information for Catherine West more like this
1005715
star this property registered interest false more like this
star this property date less than 2018-11-12more like thismore than 2018-11-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the financial cost offset to the NHS including savings to the NHS from reduced acquisition costs of food supplements of commissioning Kuvan for the treatment of phenylketonuria. more like this
star this property tabling member constituency Hornsey and Wood Green more like this
star this property tabling member printed
Catherine West more like this
star this property uin 190519 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2018-11-20more like thismore than 2018-11-20
star this property answer text <p>NHS England has considered a policy for Kuvan (sapropterin) at the Clinical Priorities Advisory Group (CPAG) meeting on 6/7 November. Whilst NHS England did make an estimate of the current cost of protein supplements and a potential reduction in their use if Kuvan were prescribed, this cost was not included in the analysis because commissioning responsibility for supplements rests with clinical commissioning groups and it would be unlikely that NHS England would be able to realise these savings. The cost of the potential reduction in protein supplements is also relatively modest compared to the cost of Kuvan.</p><p> </p><p>In line with its published process, the recommendations from CPAG will be considered by the Specialised Commissioning Oversight Group and the Specialised Services Commissioning Committee. A decision about whether or not Kuvan has been prioritised for funding will be published in due course.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Kuvan for the treatment of phenylketonuria. In developing technology appraisal guidance, NICE takes into account all the health and publicly funded social care related costs and benefits associated with the treatment, potentially including any costs from NHS funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property grouped question UIN 190518 more like this
star this property question first answered
less than 2018-11-20T15:25:36.67Zmore like thismore than 2018-11-20T15:25:36.67Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4523
star this property label Biography information for Catherine West more like this
931828
star this property registered interest false more like this
star this property date less than 2018-06-27more like thismore than 2018-06-27
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, what the timescale is for NICE to review the commissioning report for Kuvan. more like this
star this property tabling member constituency Hornsey and Wood Green more like this
star this property tabling member printed
Catherine West more like this
star this property uin 158304 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2018-07-05more like thismore than 2018-07-05
star this property answer text <p>Kuvan is being considered in the topic selection process at the National Institute for Health and Care Excellence (NICE) and will be discussed by the topic selection group in September. If consensus is reached with all the decision makers, NICE will develop a scope which defines the disease, the patients and the technologies covered by the appraisal and the questions it aims to answer. This will then be subject to consultation in September.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-07-05T10:53:30.027Zmore like thismore than 2018-07-05T10:53:30.027Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4523
star this property label Biography information for Catherine West more like this
885233
star this property registered interest false more like this
star this property date less than 2018-04-17more like thismore than 2018-04-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Parliamentary Under Secretary of State for Mental Health and Inequalities on 22 March, Col 488, what recent discussions he has had with BioMarin, the manufacturer of Kuvan, on the pricing of that drug. more like this
star this property tabling member constituency Easington more like this
star this property tabling member printed
Grahame Morris more like this
star this property uin 136098 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2018-04-24more like thismore than 2018-04-24
star this property answer text <p>NHS England has advised that they have, over the last three years, received fewer than 10 Individual Funding Requests applications and therefore there have been fewer than 10 approvals relating to the use of Kuvan.</p><p> </p><p>The Secretary of State for Health and Social Care has not had further recent discussions with the manufacturer (BioMarin) since the oral contribution of my Rt. hon. Friend the Parliamentary Under Secretary of State for Mental Health and Inequalities (Jackie Doyle-Price).</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property grouped question UIN 136042 more like this
star this property question first answered
less than 2018-04-24T15:36:59.493Zmore like thismore than 2018-04-24T15:36:59.493Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3973
star this property label Biography information for Grahame Morris more like this
885054
star this property registered interest false more like this
star this property date less than 2018-04-16more like thismore than 2018-04-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Sapropterin remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health and Social Care, how many individual patient funding requests have been approved for the use of Kuvan. more like this
star this property tabling member constituency Easington more like this
star this property tabling member printed
Grahame Morris more like this
star this property uin 136042 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2018-04-24more like thismore than 2018-04-24
star this property answer text <p>NHS England has advised that they have, over the last three years, received fewer than 10 Individual Funding Requests applications and therefore there have been fewer than 10 approvals relating to the use of Kuvan.</p><p> </p><p>The Secretary of State for Health and Social Care has not had further recent discussions with the manufacturer (BioMarin) since the oral contribution of my Rt. hon. Friend the Parliamentary Under Secretary of State for Mental Health and Inequalities (Jackie Doyle-Price).</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property grouped question UIN 136098 more like this
star this property question first answered
less than 2018-04-24T15:36:59.447Zmore like thismore than 2018-04-24T15:36:59.447Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
3973
star this property label Biography information for Grahame Morris more like this